Literature DB >> 33923087

A Systematic Review and Meta-Analysis of Pharmacogenetic Studies in Patients with Chronic Kidney Disease.

Maria Tziastoudi1, Georgios Pissas1, Georgios Raptis2, Christos Cholevas3, Theodoros Eleftheriadis1, Evangelia Dounousi4, Ioannis Stefanidis1, Theoharis C Theoharides5.   

Abstract

Chronic kidney disease (CKD) is an important global public health problem due to its high prevalence and morbidity. Although the treatment of nephrology patients has changed considerably, ineffectiveness and side effects of medications represent a major issue. In an effort to elucidate the contribution of genetic variants located in several genes in the response to treatment of patients with CKD, we performed a systematic review and meta-analysis of all available pharmacogenetics studies. The association between genotype distribution and response to medication was examined using the dominant, recessive, and additive inheritance models. Subgroup analysis based on ethnicity was also performed. In total, 29 studies were included in the meta-analysis, which examined the association of 11 genes (16 polymorphisms) with the response to treatment regarding CKD. Among the 29 studies, 18 studies included patients with renal transplantation, 8 involved patients with nephrotic syndrome, and 3 studies included patients with lupus nephritis. The present meta-analysis provides strong evidence for the contribution of variants harbored in the ABCB1, IL-10, ITPA, MIF, and TNF genes that creates some genetic predisposition that reduces effectiveness or is associated with adverse events of medications used in CKD.

Entities:  

Keywords:  chronic kidney disease; genetic association; meta-analysis; pharmacogenetics; systematic review

Year:  2021        PMID: 33923087     DOI: 10.3390/ijms22094480

Source DB:  PubMed          Journal:  Int J Mol Sci        ISSN: 1422-0067            Impact factor:   5.923


  52 in total

1.  Clinical Pharmacogenomics: Applications in Nephrology.

Authors:  Solomon M Adams; Karryn R Crisamore; Philip E Empey
Journal:  Clin J Am Soc Nephrol       Date:  2018-05-23       Impact factor: 8.237

2.  CYP3A5 and ABCB1 polymorphisms in donor and recipient: impact on Tacrolimus dose requirements and clinical outcome after renal transplantation.

Authors:  François Glowacki; Arnaud Lionet; David Buob; Myriam Labalette; Delphine Allorge; François Provôt; Marc Hazzan; Christian Noël; Franck Broly; Christelle Cauffiez
Journal:  Nephrol Dial Transplant       Date:  2011-06-15       Impact factor: 5.992

Review 3.  Effect of CYP3A and ABCB1 single nucleotide polymorphisms on the pharmacokinetics and pharmacodynamics of calcineurin inhibitors: Part II.

Authors:  Christine E Staatz; Lucy K Goodman; Susan E Tett
Journal:  Clin Pharmacokinet       Date:  2010-04       Impact factor: 6.447

4.  Association of macrophage migration inhibitory factor -173C allele polymorphism with steroid resistance in children with nephrotic syndrome.

Authors:  Afig Berdeli; Sevgi Mir; Nese Ozkayin; Erkin Serdaroglu; Yilmaz Tabel; Alphan Cura
Journal:  Pediatr Nephrol       Date:  2005-08-16       Impact factor: 3.714

Review 5.  Pharmacogenomics: a new paradigm to personalize treatments in nephrology patients.

Authors:  G Zaza; S Granata; F Sallustio; G Grandaliano; F P Schena
Journal:  Clin Exp Immunol       Date:  2009-11-24       Impact factor: 4.330

6.  Impact of the heterozygous TPMT*1/*3C genotype on azathioprine-induced myelosuppression in kidney transplant recipients in Thailand.

Authors:  Suda Vannaprasaht; Susothorn Angsuthum; Yingyos Avihingsanon; Dhavee Sirivongs; Cholatip Pongskul; Pattarapong Makarawate; Kearkiat Praditpornsilpa; Wongwiwat Tassaneeyakul; Wichittra Tassaneeyakul
Journal:  Clin Ther       Date:  2009-07       Impact factor: 3.393

7.  Association of four DNA polymorphisms with acute rejection after kidney transplantation.

Authors:  Josep Grinyó; Yves Vanrenterghem; Björn Nashan; Flavio Vincenti; Henrik Ekberg; Klaus Lindpaintner; Michelle Rashford; Clare Nasmyth-Miller; Athina Voulgari; Olivia Spleiss; Matthew Truman; Laurent Essioux
Journal:  Transpl Int       Date:  2008-04-25       Impact factor: 3.782

8.  Association of MDR1, CYP3A4*18B, and CYP3A5*3 polymorphisms with cyclosporine pharmacokinetics in Chinese renal transplant recipients.

Authors:  Xiao-Yan Qiu; Zheng Jiao; Ming Zhang; Long-Jin Zhong; Hui-Qi Liang; Chun-Lai Ma; Liang Zhang; Ming-Kang Zhong
Journal:  Eur J Clin Pharmacol       Date:  2008-07-18       Impact factor: 2.953

9.  Interleukin-10 gene promoter polymorphisms are associated with cyclosporin A-induced gingival overgrowth in renal transplant patients.

Authors:  Yixi Luo; Yiming Gong; Youcheng Yu
Journal:  Arch Oral Biol       Date:  2013-05-02       Impact factor: 2.633

Review 10.  Inflammation is a major regulator of drug metabolizing enzymes and transporters: Consequences for the personalization of drug treatment.

Authors:  Françoise Stanke-Labesque; Elodie Gautier-Veyret; Stephanie Chhun; Romain Guilhaumou
Journal:  Pharmacol Ther       Date:  2020-07-11       Impact factor: 12.310

View more
  1 in total

Review 1.  The Evolving Role of Diagnostic Genomics in Kidney Transplantation.

Authors:  Jacqueline Soraru; Aron Chakera; Nikky Isbel; Amali Mallawaarachichi; Natasha Rogers; Peter Trnka; Chirag Patel; Andrew J Mallett
Journal:  Kidney Int Rep       Date:  2022-05-25
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.